ACP's advice is for average risk adults without symptoms
Philadelphia, May 19, 2015 -- In a paper published today in Annals of Internal Medicine, the American College of Physicians (ACP) issued : breast, colorectal, ovarian, prostate, and cervical.
In a companion piece also published in Annals, ACP outlined a .
"ACP wants smarter screening by informing people about the benefits and harms of screening and encouraging them to get screened at the right time, at the right interval, with the right test," said Dr. Wayne J. Riley, president, ACP. "Many people have a lack of understanding about the trade-offs of screening. Study after study has consistently shown that patients and many physicians overestimate the benefits and are unaware of and/or downplay the potential harms of cancer screening."
In "Screening for Cancer," ACP reviewed clinical guidelines and evidence synthesis issued by the U.S. Preventive Services Task Force, the American Academy of Family Physicians, the American Cancer Society, the American Congress of Obstetrics and Gynecology, the American Gastroenterological Association, the American Urological Association, and ACP.
"We found much common agreement on high value care screening among different organizations," said Dr. Tanveer Mir, chair of ACP's Board of Regents and a member of ACP's High Value Care Task Force, which developed the papers. "Our advice puts that agreement together in one convenient place for physicians and patients. Many major physician organizations are seeking to implement strategies that best optimize the known benefits and harms of cancer screenings."
Various screening strategies exist for each of the cancers highlighted in the paper. High intensity screening strategies (screening broader populations, more frequently, and/or with more sensitive screening tests) are not necessarily high value care. ACP defines high value care as the delivery of services providing benefits that make their harms and costs worthwhile. ACP encourages physicians to implement a health care strategy that focuses on tests or treatments that improve health, avoid harms, and eliminate wasteful practices.
Screening average risk adults ages 50 to 75 for colorectal cancer with high sensitivity fecal occult blood testing every year is an example of high value care. Screening women without a cervix for cervical cancer is an example of low value care.
"The largest harm that can result from overly intense screening is over-diagnosis and overtreatment," Dr. Riley said. "The more sensitive the test we use or lower the threshold we establish for an abnormality the more abnormalities we find -- many of which will never lead to health problems. But because doctors cannot know which of these would or would not cause problems, we tend to treat them. Treatment for cell and tissue abnormalities that will likely not cause health problems cannot provide benefits."
Prostate cancer, for example, detected with the prostate-specific antigen (PSA) test never becomes clinically significant in a patient's lifetime in a considerable proportion of men. Screening using the PSA test in average risk men under the age of 50 years or over the age of 69 years can open the door to more testing and treatment that might actually be harmful. If cancer is diagnosed, it will often be treated with surgery or radiation, which increases the risk for loss of sexual function and loss of control of urination compared to no surgery. This does not apply to those men considered to be in high risk groups such as African American men and/or those with a strong family history of prostate cancer.
.
In "A Value Framework for Cancer Screening," ACP speculates about pressures that encourage overly intensive low value screening. The paper lists and discusses five general concepts:
- Screening is a cascade of events rather than a single test.
- Cancers are heterogeneous. Optimal intensity screening strategies seek to find that subset of abnormalities that has the greatest probability of progressing to cause health problems and that is more treatable at an early, asymptomatic stage.
- Individuals are heterogeneous. Optimal intensity screening strategies focus on people with sufficient risk of having a potentially fatal cancer who also have low competing health risks from other causes.
- Although screening leads to important benefits for some cancers and some people, it can also lead to significant harms to many more people than those receiving benefits.
- Determining the value of screening strategies is complex, but not impossible.
About ACP's High Value Care Task Force
is designed to help doctors and patients
understand the benefits, harms, and costs of tests and treatment
options for common clinical issues so they can pursue care together
that improves health, avoids harms, and eliminates wasteful
practices. ACP defines High Value Care as the delivery of services
providing benefits that make their harms and costs worthwhile.
ACP's High Value Care Task Force papers focus on value by
evaluating the benefits, harms, and costs of a test or
intervention. Value is not merely cost. Some expensive tests and
treatments have high value because they provide high benefit and
low harm. Conversely, some inexpensive tests or treatments have low
value because they do not provide enough benefit to justify even
their low costs and might even be harmful.
About the Â鶹ֱ²¥app
The Â鶹ֱ²¥app is the largest
medical specialty organization and the second-largest physician
group in the United States. ACP members include 141,000 internal
medicine physicians (internists), related subspecialists, and
medical students. Internal medicine physicians are specialists who
apply scientific knowledge and clinical expertise to the diagnosis,
treatment, and compassionate care of adults across the spectrum
from health to complex illness. Follow ACP on and .